NEW BRUNSWICK, N.J.,
Jan. 26, 2016 /PRNewswire/ -- Johnson
& Johnson (NYSE: JNJ) today announced sales of $17.8 billion for the fourth quarter of 2015, a
decrease of 2.4% as compared to the fourth quarter of 2014.
Operational sales results increased 4.4% and the negative
impact of currency was 6.8%. Domestic sales increased 8.0%.
International sales decreased 11.7%, reflecting operational growth
of 1.2% and a negative currency impact of 12.9%. Excluding the net
impact of acquisitions, divestitures and hepatitis C sales, on an
operational basis, worldwide sales increased 7.8%, domestic sales
increased 13.4% and international sales increased 2.9%.*
Worldwide sales for the full-year 2015 were $70.1 billion, a decrease of 5.7% versus
2014. Operational results increased 1.8% and the negative
impact of currency was 7.5%. Domestic sales increased
2.6%. International sales decreased 13.1%, reflecting
operational growth of 1.1% and a negative currency impact of
14.2%. Excluding the net impact of acquisitions, divestitures
and hepatitis C sales, on an operational basis, worldwide sales
increased 6.5%, domestic sales increased 10.6% and international
sales increased 3.0%.*
Net earnings and diluted earnings per share for the fourth
quarter of 2015 were $3.2 billion and
$1.15, respectively.
Fourth-quarter 2015 net earnings included after-tax
intangible amortization expense of approximately $0.2 billion and a charge for after-tax special
items of approximately $0.6 billion.
Fourth-quarter 2014 net earnings included after-tax intangible
amortization expense of approximately $0.3
billion and a charge for after-tax special items of
approximately $1.1 billion. A
reconciliation of non-GAAP financial measures is included as an
accompanying schedule. Excluding after-tax intangible
amortization expense and special items, adjusted net earnings for
the current quarter were $4.0 billion
and adjusted diluted earnings per share were $1.44, representing increases of 4.0% and 5.1%,
respectively, as compared to the same period in 2014.* On an
operational basis, adjusted diluted earnings per share increased
12.4%.*
Net earnings and diluted earnings per share for the full-year
2015 were $15.4 billion and
$5.48, respectively. Full-year
net earnings included after-tax intangible amortization expense of
approximately $1.1 billion and a net
charge for after-tax special items of approximately $0.9 billion. Full-year 2014 net earnings
included after-tax intangible amortization expense of approximately
$1.2 billion and a net charge for
after-tax special items of approximately $0.8 billion. A reconciliation of non-GAAP
financial measures is included as an accompanying schedule.
Excluding after-tax intangible amortization expense and special
items, adjusted net earnings for the full-year of 2015 were
$17.4 billion and adjusted diluted
earnings per share were $6.20,
representing decreases of 4.8% and 3.0%, respectively, as compared
to the full year of 2014.* On an operational basis, adjusted
diluted earnings per share increased 5.8%.*
"Johnson & Johnson delivered strong underlying growth in
2015, driven by the performance of our Pharmaceutical business and
iconic Consumer brands," said Alex
Gorsky, Chairman and Chief Executive Officer. "As we
enter 2016, our core business is very healthy, and the recent
decisive actions we've taken in support of each of our businesses
position us well to drive sustainable long-term growth, faster than
the markets we compete in."
Mr. Gorsky continued, "I want to thank all of our colleagues for
contributing to these results through their commitment and
dedication to the people around the world who rely on our
products."
The company announced its 2016 full-year guidance for sales of
$70.8 billion to $71.5 billion
reflecting expected operational growth in the range of 2.5% to
3.5%. Excluding the impact of acquisitions, divestitures and
hepatitis C sales, operational sales growth is expected to be in
the range of 4.5% to 6.0%.* Additionally, the company
announced adjusted earnings guidance for full-year 2016 of
$6.43 to $6.58 per share reflecting
expected operational growth in the range of 5.3% to 7.7%.*
Adjusted earnings guidance excludes the impact of after-tax
intangible amortization expense and special items.
Worldwide Consumer sales of $13.5
billion for the full-year 2015 represented a decrease of
6.8% versus the prior year, consisting of an operational increase
of 2.7% and a negative impact from currency of 9.5%. Domestic sales
increased 2.5%; international sales decreased 11.9%, which
reflected an operational increase of 2.7% and a negative currency
impact of 14.6%. Excluding the net impact of acquisitions and
divestitures, on an operational basis, worldwide sales increased
4.1%, domestic sales increased 4.6% and international sales
increased 3.8%.*
Positive contributors to Consumer operational results were sales
of over-the-counter products including TYLENOL® and
MOTRIN® analgesics, upper respiratory products including
ZYRTEC® allergy medications, and digestive health
products; international feminine protection products;
LISTERINE® oral care products; and
NEUTROGENA® skin care products.
Worldwide Pharmaceutical sales of $31.4
billion for the full-year 2015 represented a decrease of
2.7% versus the prior year with an operational increase of 4.2% and
a negative impact from currency of 6.9%. Domestic sales increased
5.2%; international sales decreased 12.0%, which reflected an
operational increase of 3.0% and a negative currency impact of
15.0%. Excluding the net impact of acquisitions, divestitures
and hepatitis C sales, on an operational basis, worldwide sales
increased 11.0%, domestic sales increased 18.1% and international
sales increased 3.3%.*
Worldwide operational sales growth was driven by new products
and the strength of core products. New product sales growth was
negatively impacted by lower sales of
OLYSIO®/SOVRIAD® (simeprevir) due to
competitive entrants. Strong growth in new products include
INVOKANA®/INVOKAMET® (canagliflozin), for the
treatment of adults with type 2 diabetes; IMBRUVICA®
(ibrutinib), an oral, once-daily therapy approved for use in
treating certain B-cell malignancies, or blood cancers;
XARELTO® (rivaroxaban), an oral anticoagulant; and
ZYTIGA® (abiraterone acetate), an oral, once-daily
medication for use in combination with prednisone for the treatment
of metastatic, castration-resistant prostate cancer.
Additional contributors to operational sales growth were
STELARA® (ustekinumab), a biologic approved for the
treatment of moderate to severe plaque psoriasis and psoriatic
arthritis; INVEGA®
SUSTENNA®/XEPLION®/TRINZA®
(paliperidone palmitate), long-acting, injectable atypical
antipsychotics for the treatment of schizophrenia in adults;
CONCERTA® (methylphenidate HCI), for the treatment of
attention deficit hyperactivity disorder; and
SIMPONI®/SIMPONI ARIA® (golimumab), biologics
approved for the treatment of a number of immune-mediated
inflammatory diseases.
During the quarter, the U.S. Food and Drug Administration (FDA)
approved DARZALEX™ (daratumumab) for the treatment of double
refractory multiple myeloma. Additionally, the FDA approved
YONDELIS® (trabectedin) for the treatment of patients
with unresectable or metastatic liposarcoma or
leiomyosarcoma. The European Commission approved
EDURANT® (rilpiravine) in combination with other
anti-retroviral agents, for treatment-naïve adolescent patients
aged 12 to 18 years with human immunodeficiency virus-1 (HIV-1)
infection.
In the U.S., a New Drug Application (NDA) was submitted for
INVOKAMET® XR, a once-daily therapy combining fixed
doses of canagliflozin and metformin hydrochloride extended release
for the treatment of adults with type 2 diabetes.
Additionally, regulatory applications were submitted for
STELARA® (ustekinumab) for the treatment of adult
patients with moderately to severely active Crohn's disease to the
FDA and the European Medicines Agency (EMA). Several
regulatory submissions were completed for additional indications of
IMBRUVICA® (ibrutinib) including for patients with
relapsed or refractory chronic lymphocytic leukemia (CLL) or small
lymphocytic lymphoma in combination with bendamustine and rituximab
in both the U.S. and the European Union (EU) as well as for use in
treatment-naïve patients with CLL and relapsed/refractory patients
with mantle cell lymphoma in the EU.
Also in the quarter, the acquisition of Novira Therapeutics,
Inc., a privately held clinical-stage biopharmaceutical company
developing innovative therapies for curative treatment of chronic
hepatitis B virus infection, was completed.
Worldwide Medical Devices sales of $25.1
billion for the full-year represented a decrease of 8.7%
versus the prior year consisting of an operational decrease of 1.4%
and a negative currency impact of 7.3%. Domestic sales decreased
1.0%; international sales decreased 14.8%, which reflected an
operational decrease of 1.7% and a negative currency impact of
13.1%. Excluding the net impact of acquisitions and divestitures,
on an operational basis, worldwide sales increased 2.5%, domestic
sales increased 3.3% and international sales increased
2.0%.*
Primary contributors to operational growth were sales of
endocutters and biosurgical products in the Advanced Surgery
business; electrophysiology products in the Cardiovascular
business; joint reconstruction products in the Orthopaedics
business; and insulin pump products in the Diabetes Care
business.
During the quarter, the pediatric indication for the
Animas® Vibe® insulin pump was approved by
the FDA. Also in the quarter, the acquisition of Coherex
Medical, Inc., a privately held medical device company focused on
the development of the Coherex WaveCrest® left atrial
appendage occlusion system, was completed.
Subsequent to the quarter, the company announced on January 19th, a restructuring of
certain Medical Devices businesses. The company's Consumer
Medical Devices businesses, Vision Care and Diabetes Care, are not
impacted by these actions. The restructuring is being undertaken to
accelerate the pace of innovation, address unmet patient needs and
drive growth. The actions are expected to result in ongoing
annualized, pre-tax cost savings of $0.8
billion to $1.0 billion, the majority of which is expected
to be realized by the end of 2018, including approximately
$200 million in 2016.
About Johnson & Johnson
Caring for the world, one person at a time, inspires and unites
the people of Johnson & Johnson. We embrace research and
science - bringing innovative ideas, products and services to
advance the health and well-being of people. Our approximately
127,000 employees at more than 250 Johnson & Johnson operating
companies work with partners in health care to touch the lives of
over a billion people every day, throughout the world.
* Operational sales growth excluding the net impact of
acquisitions, divestitures and hepatitis C sales, as well as
adjusted net earnings, adjusted diluted earnings per share and
operational adjusted diluted earnings per share excluding after-tax
intangible amortization expense and special items, are non-GAAP
financial measures and should not be considered replacements for,
and should be read together with, the most comparable GAAP
financial measures. Except for guidance measures,
reconciliations of these non-GAAP financial measures to the most
directly comparable GAAP financial measures can be found in the
accompanying financial schedules of the earnings release and the
Investor Relations section of the company's website at
www.investor.jnj.com.
Johnson & Johnson will conduct a conference call with
investors to discuss this news release today at 8:30 a.m., Eastern Time. A simultaneous webcast
of the call for investors and other interested parties may be
accessed by visiting the Johnson & Johnson website at
www.investor.jnj.com. A replay and podcast will be available
approximately two hours after the live webcast by visiting
www.investor.jnj.com.
Copies of the financial schedules accompanying this press
release are available at www.investor.jnj.com/historical-sales.cfm.
These schedules include supplementary sales data, a condensed
consolidated statement of earnings, reconciliations of non-GAAP
financial measures, and sales of key products/franchises.
Additional information on Johnson & Johnson, including
adjusted income before tax by segment, a pharmaceutical pipeline of
selected compounds in late stage development and a copy of today's
earnings call presentation can be found on the company's website at
www.investor.jnj.com.
NOTE TO INVESTORS
This press release contains "forward-looking statements" as
defined in the Private Securities Litigation Reform Act of 1995
regarding, among other things, future operating and financial
performance, product development, market position, business
strategy and restructuring plans. The reader is cautioned not to
rely on these forward-looking statements. These statements are
based on current expectations of future events. If underlying
assumptions prove inaccurate or known or unknown risks or
uncertainties materialize, actual results could vary materially
from the expectations and projections of Johnson & Johnson.
Risks and uncertainties include, but are not limited to, economic
factors, such as interest rate and currency exchange rate
fluctuations; competition, including technological advances, new
products and patents attained by competitors; challenges and
uncertainties inherent in new product development, including
uncertainty of clinical success and obtaining regulatory approvals;
uncertainty of commercial success for new and existing products;
impact of business combinations and divestitures; challenges to
patents; the impact of patent expirations; the ability of the
company to successfully execute strategic plans, including
restructuring plans; any required consultation procedures relating
to the restructuring workforce actions; the potential that the
expected benefits and opportunities related to the restructuring
may not be realized or may take longer to realize than expected;
market conditions and the possibility that the on-going share
repurchase program may be suspended or discontinued; significant
adverse litigation or government action, including related to
product liability claims; changes to applicable laws and
regulations, including global health care reforms; trends toward
health care cost containment; changes in behavior and spending
patterns or financial distress of purchasers of health care
products and services; financial instability of international
economies and legal systems and sovereign risk; manufacturing
difficulties or delays, internally or within the supply chain;
product efficacy or safety concerns resulting in product recalls or
regulatory action; increased scrutiny of the health care industry
by government agencies; and the potential failure to meet
obligations in compliance agreements with government bodies. A
further list and description of these risks, uncertainties and
other factors can be found in Johnson & Johnson's Annual Report
on Form 10-K for the fiscal year ended December 28, 2014, including Exhibit 99 thereto,
and the company's subsequent filings with the Securities and
Exchange Commission. Copies of these filings are available online
at www.sec.gov, www.investor.jnj.com, or on request from Johnson
& Johnson. Any forward-looking statement made in this release
speaks only as of the date of this release. Johnson & Johnson
does not undertake to update any forward-looking statements as a
result of new information or future events or developments.
Johnson &
Johnson and Subsidiaries
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Supplementary
Sales Data
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(Unaudited; Dollars
in Millions)
|
FOURTH
QUARTER
|
|
TWELVE
MONTHS
|
|
|
|
|
|
Percent
Change
|
|
|
|
|
|
Percent
Change
|
|
2015
|
|
2014
|
|
Total
|
|
Operations
|
|
Currency
|
|
2015
|
|
2014
|
|
Total
|
|
Operations
|
|
Currency
|
Sales to customers
by
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
segment of
business
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Consumer
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
U.S.
|
$ 1,231
|
|
1,294
|
|
(4.9)
|
%
|
(4.9)
|
|
-
|
|
$ 5,222
|
|
5,096
|
|
2.5
|
%
|
2.5
|
|
-
|
International
|
2,089
|
|
2,312
|
|
(9.6)
|
|
5.5
|
|
(15.1)
|
|
8,285
|
|
9,400
|
|
(11.9)
|
|
2.7
|
|
(14.6)
|
|
3,320
|
|
3,606
|
|
(7.9)
|
|
1.8
|
|
(9.7)
|
|
13,507
|
|
14,496
|
|
(6.8)
|
|
2.7
|
|
(9.5)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Pharmaceutical
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
U.S.
|
4,910
|
|
4,356
|
|
12.7
|
|
12.7
|
|
-
|
|
18,333
|
|
17,432
|
|
5.2
|
|
5.2
|
|
-
|
International
|
3,154
|
|
3,643
|
|
(13.4)
|
|
(0.9)
|
|
(12.5)
|
|
13,097
|
|
14,881
|
|
(12.0)
|
|
3.0
|
|
(15.0)
|
|
8,064
|
|
7,999
|
|
0.8
|
|
6.5
|
|
(5.7)
|
|
31,430
|
|
32,313
|
|
(2.7)
|
|
4.2
|
|
(6.9)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Medical
Devices
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
U.S.
|
3,152
|
|
2,954
|
|
6.7
|
|
6.7
|
|
-
|
|
12,132
|
|
12,254
|
|
(1.0)
|
|
(1.0)
|
|
-
|
International
|
3,275
|
|
3,695
|
|
(11.4)
|
|
0.6
|
|
(12.0)
|
|
13,005
|
|
15,268
|
|
(14.8)
|
|
(1.7)
|
|
(13.1)
|
|
6,427
|
|
6,649
|
|
(3.3)
|
|
3.4
|
|
(6.7)
|
|
25,137
|
|
27,522
|
|
(8.7)
|
|
(1.4)
|
|
(7.3)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
U.S.
|
9,293
|
|
8,604
|
|
8.0
|
|
8.0
|
|
-
|
|
35,687
|
|
34,782
|
|
2.6
|
|
2.6
|
|
-
|
International
|
8,518
|
|
9,650
|
|
(11.7)
|
|
1.2
|
|
(12.9)
|
|
34,387
|
|
39,549
|
|
(13.1)
|
|
1.1
|
|
(14.2)
|
Worldwide
|
$ 17,811
|
|
18,254
|
|
(2.4)
|
%
|
4.4
|
|
(6.8)
|
|
$ 70,074
|
|
74,331
|
|
(5.7)
|
%
|
1.8
|
|
(7.5)
|
Johnson &
Johnson and Subsidiaries
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Supplementary
Sales Data
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(Unaudited; Dollars
in Millions)
|
FOURTH
QUARTER
|
|
TWELVE
MONTHS
|
|
|
|
|
|
Percent
Change
|
|
|
|
|
|
Percent
Change
|
|
2015
|
|
2014
|
|
Total
|
|
Operations
|
|
Currency
|
|
2015
|
|
2014
|
|
Total
|
|
Operations
|
|
Currency
|
Sales to customers
by
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
geographic
area
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
U.S.
|
$ 9,293
|
|
8,604
|
|
8.0
|
%
|
8.0
|
|
-
|
|
$ 35,687
|
|
34,782
|
|
2.6
|
%
|
2.6
|
|
-
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Europe
|
4,002
|
|
4,560
|
|
(12.2)
|
|
0.8
|
|
(13.0)
|
|
15,995
|
|
18,947
|
|
(15.6)
|
|
1.1
|
|
(16.7)
|
Western Hemisphere
excluding U.S.
|
1,442
|
|
1,782
|
|
(19.1)
|
|
2.8
|
|
(21.9)
|
|
6,045
|
|
7,160
|
|
(15.6)
|
|
2.6
|
|
(18.2)
|
Asia-Pacific,
Africa
|
3,074
|
|
3,308
|
|
(7.1)
|
|
0.9
|
|
(8.0)
|
|
12,347
|
|
13,442
|
|
(8.1)
|
|
0.3
|
|
(8.4)
|
International
|
8,518
|
|
9,650
|
|
(11.7)
|
|
1.2
|
|
(12.9)
|
|
34,387
|
|
39,549
|
|
(13.1)
|
|
1.1
|
|
(14.2)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Worldwide
|
$ 17,811
|
|
18,254
|
|
(2.4)
|
%
|
4.4
|
|
(6.8)
|
|
$ 70,074
|
|
74,331
|
|
(5.7)
|
%
|
1.8
|
|
(7.5)
|
Johnson &
Johnson and Subsidiaries
|
|
|
|
|
|
|
|
|
|
Condensed
Consolidated Statement of Earnings
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(Unaudited; in
Millions Except Per Share Figures)
|
FOURTH
QUARTER
|
|
|
|
|
|
|
|
|
|
|
|
2015
|
|
2014
|
|
Percent
|
|
|
|
Percent
|
|
|
|
Percent
|
|
Increase
|
|
Amount
|
|
to
Sales
|
|
Amount
|
|
to
Sales
|
|
(Decrease)
|
Sales to
customers
|
$ 17,811
|
|
100.0
|
|
$ 18,254
|
|
100.0
|
|
(2.4)
|
Cost of products
sold
|
5,673
|
|
31.8
|
|
5,853
|
|
32.1
|
|
(3.1)
|
Selling, marketing
and administrative expenses
|
5,891
|
|
33.1
|
|
5,822
|
|
31.9
|
|
1.2
|
Research and
development expense
|
2,864
|
|
16.1
|
|
2,635
|
|
14.4
|
|
8.7
|
In-process
research and development
|
214
|
|
1.2
|
|
156
|
|
0.8
|
|
|
Interest (income)
expense, net
|
107
|
|
0.6
|
|
122
|
|
0.7
|
|
|
Other (income)
expense, net
|
(1,205)
|
|
(6.8)
|
|
963
|
|
5.3
|
|
|
Restructuring
|
509
|
|
2.9
|
|
-
|
|
-
|
|
|
Earnings before
provision for taxes on income
|
3,758
|
|
21.1
|
|
2,703
|
|
14.8
|
|
39.0
|
Provision for
taxes on income
|
543
|
|
3.0
|
|
182
|
|
1.0
|
|
|
Net
earnings
|
$ 3,215
|
|
18.1
|
|
$ 2,521
|
|
13.8
|
|
27.5
|
|
|
|
|
|
|
|
|
|
|
Net earnings per
share (Diluted)
|
$ 1.15
|
|
|
|
$ 0.89
|
|
|
|
29.2
|
|
|
|
|
|
|
|
|
|
|
Average shares
outstanding (Diluted)
|
2,803.3
|
|
|
|
2,845.3
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Effective tax
rate
|
14.4
|
%
|
|
|
6.7
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Adjusted earnings
before provision for taxes and net earnings (1)
|
|
|
|
|
|
|
|
|
|
Earnings before
provision for taxes on income
|
$ 4,913
|
|
27.6
|
|
$ 4,296
|
|
23.5
|
|
14.4
|
Net
earnings
|
$ 4,043
|
|
22.7
|
|
$ 3,887
|
|
21.3
|
|
4.0
|
Net earnings per
share (Diluted)
|
$ 1.44
|
|
|
|
$ 1.37
|
|
|
|
5.1
|
Effective tax
rate
|
17.7
|
%
|
|
|
9.5
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) See
Reconciliation of Non-GAAP Financial Measures.
|
|
|
|
|
|
|
|
|
|
Johnson &
Johnson and Subsidiaries
|
|
|
|
|
|
|
|
|
|
Condensed
Consolidated Statement of Earnings
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(Unaudited; in
Millions Except Per Share Figures)
|
TWELVE
MONTHS
|
|
|
|
|
|
|
|
|
|
|
|
2015
|
|
2014
|
|
Percent
|
|
|
|
Percent
|
|
|
|
Percent
|
|
Increase
|
|
Amount
|
|
to
Sales
|
|
Amount
|
|
to
Sales
|
|
(Decrease)
|
Sales to
customers
|
$ 70,074
|
|
100.0
|
|
$ 74,331
|
|
100.0
|
|
(5.7)
|
Cost of products
sold
|
21,536
|
|
30.7
|
|
22,746
|
|
30.6
|
|
(5.3)
|
Selling, marketing
and administrative expenses
|
21,203
|
|
30.3
|
|
21,954
|
|
29.5
|
|
(3.4)
|
Research and
development expense
|
9,046
|
|
12.9
|
|
8,494
|
|
11.4
|
|
6.5
|
In-process
research and development
|
224
|
|
0.3
|
|
178
|
|
0.3
|
|
|
Interest (income)
expense, net
|
424
|
|
0.6
|
|
466
|
|
0.6
|
|
|
Other (income)
expense, net
|
(2,064)
|
|
(2.9)
|
|
(70)
|
|
(0.1)
|
|
|
Restructuring
|
509
|
|
0.7
|
|
-
|
|
-
|
|
|
Earnings before
provision for taxes on income
|
19,196
|
|
27.4
|
|
20,563
|
|
27.7
|
|
(6.6)
|
Provision for
taxes on income
|
3,787
|
|
5.4
|
|
4,240
|
|
5.7
|
|
(10.7)
|
Net
earnings
|
$ 15,409
|
|
22.0
|
|
$ 16,323
|
|
22.0
|
|
(5.6)
|
|
|
|
|
|
|
|
|
|
|
Net earnings per
share (Diluted)
|
$ 5.48
|
|
|
|
$ 5.70
|
|
|
|
(3.9)
|
|
|
|
|
|
|
|
|
|
|
Average shares
outstanding (Diluted)
|
2,812.9
|
|
|
|
2,863.9
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Effective tax
rate
|
19.7
|
%
|
|
|
20.6
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Adjusted earnings
before provision for taxes and net earnings (1)
|
|
|
|
|
|
|
|
|
|
Earnings before
provision for taxes on income
|
$ 22,003
|
|
31.4
|
|
$ 22,825
|
|
30.7
|
|
(3.6)
|
Net
earnings
|
$ 17,445
|
|
24.9
|
|
$ 18,318
|
|
24.6
|
|
(4.8)
|
Net earnings per
share (Diluted)
|
$ 6.20
|
|
|
|
$ 6.39
|
|
|
|
(3.0)
|
Effective tax
rate
|
20.7
|
%
|
|
|
19.7
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) See
Reconciliation of Non-GAAP Financial Measures.
|
|
|
|
|
|
|
|
|
|
Johnson &
Johnson and Subsidiaries
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Reconciliation of
Non-GAAP Financial Measures
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Fourth
Quarter
|
|
% Incr. /
|
|
|
Twelve
Months
|
|
% Incr. /
|
|
(Dollars in
Millions Except Per Share Data)
|
2015
|
|
2014
|
|
(Decr.)
|
|
|
2015
|
|
2014
|
|
(Decr.)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Earnings before
provision for taxes on income - as reported
|
$ 3,758
|
|
2,703
|
|
39.0
|
%
|
|
$ 19,196
|
|
20,563
|
|
(6.6)
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Intangible asset
amortization expense
|
301
|
|
371
|
|
|
|
|
1,570
|
|
1,630
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Restructuring
(1)
|
590
|
|
-
|
|
|
|
|
590
|
|
-
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
In-process research
and development
|
214
|
|
156
|
|
|
|
|
224
|
|
178
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Synthes integration
costs
|
83
|
|
325
|
|
|
|
|
196
|
|
754
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
DePuy ASR™ Hip program
|
-
|
|
-
|
|
|
|
|
148
|
|
126
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Litigation expense,
net
|
-
|
|
692
|
|
|
|
|
141
|
|
1,253
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Ortho-Clinical
Diagnostics divestiture net (gain)/expense
|
(33)
|
|
49
|
|
|
|
|
(62)
|
|
(1,899)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Additional year of
Branded Prescription Drug Fee
|
-
|
|
-
|
|
|
|
|
-
|
|
220
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Earnings before
provision for taxes on income - as adjusted
|
$ 4,913
|
|
4,296
|
|
14.4
|
%
|
|
$ 22,003
|
|
22,825
|
|
(3.6)
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net Earnings - as
reported
|
$ 3,215
|
|
2,521
|
|
27.5
|
%
|
|
$ 15,409
|
|
16,323
|
|
(5.6)
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Intangible asset
amortization expense
|
220
|
|
275
|
|
|
|
|
1,113
|
|
1,213
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Restructuring
|
415
|
|
-
|
|
|
|
|
415
|
|
-
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
In-process research
and development
|
156
|
|
115
|
|
|
|
|
162
|
|
131
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Synthes integration
costs
|
59
|
|
237
|
|
|
|
|
144
|
|
555
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
DePuy ASR™ Hip program
|
-
|
|
-
|
|
|
|
|
130
|
|
111
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Litigation expense,
net
|
-
|
|
652
|
|
|
|
|
118
|
|
1,225
|
(2)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Ortho-Clinical
Diagnostics divestiture net (gain)/expense
|
(22)
|
|
87
|
|
|
|
|
(46)
|
|
(1,062)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Additional year of
Branded Prescription Drug Fee
|
-
|
|
-
|
|
|
|
|
-
|
|
220
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Tax benefit
associated with Conor Medsystems
|
-
|
|
-
|
|
|
|
|
-
|
|
(398)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net Earnings -
as adjusted
|
$ 4,043
|
|
3,887
|
|
4.0
|
%
|
|
$ 17,445
|
|
18,318
|
|
(4.8)
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Diluted Net Earnings
per share - as reported
|
$ 1.15
|
|
0.89
|
|
29.2
|
%
|
|
$ 5.48
|
|
5.70
|
|
(3.9)
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Intangible asset
amortization expense
|
0.07
|
|
0.10
|
|
|
|
|
0.39
|
|
0.42
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Restructuring
|
0.15
|
|
-
|
|
|
|
|
0.15
|
|
-
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
In-process research
and development
|
0.06
|
|
0.04
|
|
|
|
|
0.06
|
|
0.04
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Synthes integration
costs
|
0.02
|
|
0.08
|
|
|
|
|
0.05
|
|
0.19
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
DePuy ASR™ Hip program
|
-
|
|
-
|
|
|
|
|
0.05
|
|
0.04
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Litigation expense,
net
|
-
|
|
0.23
|
|
|
|
|
0.04
|
|
0.43
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Ortho-Clinical
Diagnostics divestiture net (gain)/expense
|
(0.01)
|
|
0.03
|
|
|
|
|
(0.02)
|
|
(0.37)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Additional year of
Branded Prescription Drug Fee
|
-
|
|
-
|
|
|
|
|
-
|
|
0.08
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Tax benefit
associated with Conor Medsystems
|
-
|
|
-
|
|
|
|
|
-
|
|
(0.14)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Diluted Net Earnings
per share - as adjusted
|
$ 1.44
|
|
1.37
|
|
5.1
|
%
|
|
$ 6.20
|
|
6.39
|
|
(3.0)
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operational Diluted
Net Earnings per share - as adjusted*
|
$ 1.54
|
|
1.37
|
|
12.4
|
%
|
|
$ 6.76
|
|
6.39
|
|
5.8
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
*Excludes the effect
of translational currency
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1)Includes $81 million recorded in cost
of products sold
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(2)Includes adjustment to deferred tax
asset related to deductibility by tax jurisdiction
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Johnson &
Johnson and Subsidiaries
|
|
|
|
|
|
|
|
|
Reconciliation of
Non-GAAP Financial Measure
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operational Sales
Growth Excluding Acquisitions, Divestitures and Hepatitis C Sales
(1)
|
FOURTH
QUARTER 2015 ACTUAL vs. 2014 ACTUAL
|
|
Segments
|
|
|
Consumer
|
|
Pharmaceutical
|
|
Medical
Devices
|
|
Total
|
|
|
Operational %
(2)
|
WW As
Reported:
|
|
1.8%
|
|
6.5%
|
|
3.4%
|
|
4.4%
|
U.S.
|
|
(4.9)%
|
|
12.7%
|
|
6.7%
|
|
8.0%
|
International
|
|
5.5%
|
|
(0.9)%
|
|
0.6%
|
|
1.2%
|
|
|
|
|
|
|
|
|
|
Wound
Care/Other
|
|
|
|
|
|
|
|
|
SPLENDA
®
|
|
2.6
|
|
|
|
|
|
0.5
|
U.S.
|
|
6.5
|
|
|
|
|
|
1.0
|
International
|
|
0.3
|
|
|
|
|
|
0.1
|
|
|
|
|
|
|
|
|
|
Wound Care /
Other
|
|
|
|
|
|
|
|
|
BENECOL
®
|
|
0.3
|
|
|
|
|
|
0.1
|
U.S.
|
|
0.1
|
|
|
|
|
|
0.0
|
International
|
|
0.5
|
|
|
|
|
|
0.1
|
|
|
|
|
|
|
|
|
|
Diagnostics
|
|
|
|
|
|
|
|
|
Ortho-Clinical
Diagnostics
|
|
|
|
|
|
(0.3)
|
|
(0.1)
|
U.S.
|
|
|
|
|
|
0.0
|
|
0.0
|
International
|
|
|
|
|
|
(0.5)
|
|
(0.2)
|
|
|
|
|
|
|
|
|
|
Cardiovascular
|
|
|
|
|
|
|
|
|
Cordis
|
|
|
|
|
|
2.6
|
|
0.9
|
U.S.
|
|
|
|
|
|
1.3
|
|
0.5
|
International
|
|
|
|
|
|
3.6
|
|
1.3
|
|
|
|
|
|
|
|
|
|
Other
Neuroscience
|
|
|
|
|
|
|
|
|
NUCYNTA
®
|
|
|
|
0.5
|
|
|
|
0.2
|
U.S.
|
|
|
|
1.1
|
|
|
|
0.5
|
International
|
|
|
|
0.0
|
|
|
|
0.0
|
|
|
|
|
|
|
|
|
|
All Other
Acquisitions and Divestitures
|
|
|
|
|
|
0.1
|
|
0.1
|
U.S.
|
|
|
|
|
|
0.0
|
|
0.0
|
International
|
|
|
|
|
|
0.2
|
|
0.1
|
|
|
|
|
|
|
|
|
|
WW Ops excluding
Acquisitions and Divestitures
|
|
4.7%
|
|
7.0%
|
|
5.8%
|
|
6.1%
|
U.S.
|
|
1.7%
|
|
13.8%
|
|
8.0%
|
|
10.0%
|
International
|
|
6.3%
|
|
(0.9)%
|
|
3.9%
|
|
2.6%
|
|
|
|
|
|
|
|
|
|
Hepatitis
C
|
|
|
|
4.1
|
|
|
|
1.7
|
U.S.
|
|
|
|
7.2
|
|
|
|
3.4
|
International
|
|
|
|
0.7
|
|
|
|
0.3
|
|
|
|
|
|
|
|
|
|
WW Ops excluding
Hepatitis C only
|
|
|
|
10.6%
|
|
|
|
6.1%
|
U.S.
|
|
|
|
19.9%
|
|
|
|
11.4%
|
International
|
|
|
|
(0.2)%
|
|
|
|
1.5%
|
|
|
|
|
|
|
|
|
|
WW Ops excluding
Acquisitions, Divestitures and Hepatitis C
|
|
4.7%
|
|
11.1%
|
|
5.8%
|
|
7.8%
|
U.S.
|
|
1.7%
|
|
21.0%
|
|
8.0%
|
|
13.4%
|
International
|
|
6.3%
|
|
(0.2)%
|
|
3.9%
|
|
2.9%
|
|
|
|
|
|
|
|
|
|
(1)
Hepatitis C products include OLYSIO ®/SOVRIAD
®and INCIVO ®
|
|
|
|
|
|
|
|
|
(2)
Operational growth excludes the effect of translational
currency
|
|
|
|
|
|
|
|
|
Johnson &
Johnson and Subsidiaries
|
|
|
|
|
|
|
|
|
Reconciliation of
Non-GAAP Financial Measure
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operational Sales
Growth Excluding Acquisitions, Divestitures and Hepatitis C Sales
(1)
|
TWELVE
MONTHS 2015 ACTUAL vs. 2014 ACTUAL
|
|
|
|
|
|
|
|
|
|
Segments
|
|
|
Consumer
|
|
Pharmaceutical
|
|
Medical
Devices
|
|
Total
|
|
|
Operational %
(2)
|
WW As
Reported:
|
|
2.7%
|
|
4.2%
|
|
(1.4)%
|
|
1.8%
|
U.S.
|
|
2.5%
|
|
5.2%
|
|
(1.0)%
|
|
2.6%
|
International
|
|
2.7%
|
|
3.0%
|
|
(1.7)%
|
|
1.1%
|
|
|
|
|
|
|
|
|
|
Wound
Care/Other
|
|
|
|
|
|
|
|
|
SPLENDA
®
|
|
0.6
|
|
|
|
|
|
0.1
|
U.S.
|
|
1.7
|
|
|
|
|
|
0.2
|
International
|
|
0.1
|
|
|
|
|
|
0.0
|
|
|
|
|
|
|
|
|
|
Women's
Health
|
|
|
|
|
|
|
|
|
K-Y
®
|
|
0.3
|
|
|
|
|
|
0.1
|
U.S.
|
|
0.4
|
|
|
|
|
|
0.1
|
International
|
|
0.2
|
|
|
|
|
|
0.0
|
|
|
|
|
|
|
|
|
|
Wound Care /
Other
|
|
|
|
|
|
|
|
|
BENECOL
®
|
|
0.6
|
|
|
|
|
|
0.1
|
U.S.
|
|
0.0
|
|
|
|
|
|
0.0
|
International
|
|
0.9
|
|
|
|
|
|
0.2
|
|
|
|
|
|
|
|
|
|
Diagnostics
|
|
|
|
|
|
|
|
|
Ortho-Clinical
Diagnostics
|
|
|
|
|
|
3.2
|
|
1.2
|
U.S.
|
|
|
|
|
|
3.9
|
|
1.4
|
International
|
|
|
|
|
|
2.6
|
|
1.0
|
|
|
|
|
|
|
|
|
|
Cardiovascular
|
|
|
|
|
|
|
|
|
Cordis
|
|
|
|
|
|
0.6
|
|
0.3
|
U.S.
|
|
|
|
|
|
0.4
|
|
0.2
|
International
|
|
|
|
|
|
0.9
|
|
0.4
|
|
|
|
|
|
|
|
|
|
Other
Neuroscience
|
|
|
|
|
|
|
|
|
NUCYNTA
®
|
|
|
|
0.3
|
|
|
|
0.2
|
U.S.
|
|
|
|
0.6
|
|
|
|
0.3
|
International
|
|
|
|
0.0
|
|
|
|
0.0
|
|
|
|
|
|
|
|
|
|
All Other
Acquisitions and Divestitures
|
|
(0.1)
|
|
|
|
0.1
|
|
0.0
|
U.S.
|
|
0.0
|
|
|
|
0.0
|
|
0.0
|
International
|
|
(0.1)
|
|
|
|
0.2
|
|
0.1
|
|
|
|
|
|
|
|
|
|
WW Ops excluding
Acquisitions and Divestitures
|
|
4.1%
|
|
4.5%
|
|
2.5%
|
|
3.8%
|
U.S.
|
|
4.6%
|
|
5.8%
|
|
3.3%
|
|
4.8%
|
International
|
|
3.8%
|
|
3.0%
|
|
2.0%
|
|
2.8%
|
|
|
|
|
|
|
|
|
|
Hepatitis
C
|
|
|
|
6.5
|
|
|
|
2.7
|
U.S.
|
|
|
|
12.3
|
|
|
|
5.8
|
International
|
|
|
|
0.3
|
|
|
|
0.2
|
|
|
|
|
|
|
|
|
|
WW Ops excluding
Hepatitis C only
|
|
|
|
10.7%
|
|
|
|
4.5%
|
U.S.
|
|
|
|
17.5%
|
|
|
|
8.4%
|
International
|
|
|
|
3.3%
|
|
|
|
1.3%
|
|
|
|
|
|
|
|
|
|
WW Ops excluding
Acquisitions, Divestitures and Hepatitis C
|
|
4.1%
|
|
11.0%
|
|
2.5%
|
|
6.5%
|
U.S.
|
|
4.6%
|
|
18.1%
|
|
3.3%
|
|
10.6%
|
International
|
|
3.8%
|
|
3.3%
|
|
2.0%
|
|
3.0%
|
|
|
|
|
|
|
|
|
|
(1)
Hepatitis C products include OLYSIO ® /SOVRIAD ® and INCIVO
®
|
|
|
|
|
|
|
|
|
(2)
Operational growth excludes the effect of translational
currency
|
|
|
|
|
|
|
|
|
|
REPORTED SALES vs.
PRIOR PERIOD ($MM)
|
|
|
FOURTH
QUARTER
|
|
TWELVE
MONTHS
|
|
|
|
|
|
|
%
Change
|
|
|
|
|
|
%
Change
|
|
|
|
2015
|
|
2014
|
Reported
|
Operational
(1)
|
Currency
|
|
|
2015
|
|
2014
|
Reported
|
Operational
(1)
|
Currency
|
|
CONSUMER SEGMENT
(2)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
BABY CARE
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
$ 103
|
|
96
|
7.3%
|
7.3%
|
-
|
|
|
$ 421
|
|
407
|
3.4%
|
3.4%
|
-
|
|
Intl
|
|
381
|
|
428
|
-11.0%
|
2.8%
|
-13.8%
|
|
|
1,623
|
|
1,832
|
-11.4%
|
0.7%
|
-12.1%
|
|
WW
|
|
484
|
|
524
|
-7.6%
|
3.7%
|
-11.3%
|
|
|
2,044
|
|
2,239
|
-8.7%
|
1.2%
|
-9.9%
|
|
ORAL CARE
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
170
|
|
150
|
13.3%
|
13.3%
|
-
|
|
|
629
|
|
600
|
4.8%
|
4.8%
|
-
|
|
Intl
|
|
238
|
|
264
|
-9.8%
|
5.2%
|
-15.0%
|
|
|
951
|
|
1,047
|
-9.2%
|
5.5%
|
-14.7%
|
|
WW
|
|
408
|
|
414
|
-1.4%
|
8.2%
|
-9.6%
|
|
|
1,580
|
|
1,647
|
-4.1%
|
5.2%
|
-9.3%
|
|
OTC
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
382
|
|
362
|
5.5%
|
5.5%
|
-
|
|
|
1,536
|
|
1,357
|
13.2%
|
13.2%
|
-
|
|
Intl
|
|
663
|
|
711
|
-6.8%
|
9.4%
|
-16.2%
|
|
|
2,439
|
|
2,749
|
-11.3%
|
5.5%
|
-16.8%
|
|
WW
|
|
1,045
|
|
1,073
|
-2.6%
|
8.2%
|
-10.8%
|
|
|
3,975
|
|
4,106
|
-3.2%
|
8.1%
|
-11.3%
|
|
SKIN CARE
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
439
|
|
471
|
-6.8%
|
-6.8%
|
-
|
|
|
1,857
|
|
1,834
|
1.3%
|
1.3%
|
-
|
|
Intl
|
|
432
|
|
485
|
-10.9%
|
4.6%
|
-15.5%
|
|
|
1,674
|
|
1,924
|
-13.0%
|
1.2%
|
-14.2%
|
|
WW
|
|
871
|
|
956
|
-8.9%
|
-1.1%
|
-7.8%
|
|
|
3,531
|
|
3,758
|
-6.0%
|
1.3%
|
-7.3%
|
|
WOMEN'S
HEALTH
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
7
|
|
7
|
0.0%
|
0.0%
|
-
|
|
|
26
|
|
50
|
-48.0%
|
-48.0%
|
-
|
|
Intl
|
|
276
|
|
301
|
-8.3%
|
7.5%
|
-15.8%
|
|
|
1,174
|
|
1,252
|
-6.2%
|
9.8%
|
-16.0%
|
|
WW
|
|
283
|
|
308
|
-8.1%
|
7.4%
|
-15.5%
|
|
|
1,200
|
|
1,302
|
-7.8%
|
7.6%
|
-15.4%
|
|
WOUND CARE /
OTHER
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
130
|
|
208
|
-37.5%
|
-37.5%
|
-
|
|
|
753
|
|
848
|
-11.2%
|
-11.2%
|
-
|
|
Intl
|
|
99
|
|
123
|
-19.5%
|
-8.4%
|
-11.1%
|
|
|
424
|
|
596
|
-28.9%
|
-18.3%
|
-10.6%
|
|
WW
|
|
229
|
|
331
|
-30.8%
|
-26.7%
|
-4.1%
|
|
|
1,177
|
|
1,444
|
-18.5%
|
-14.1%
|
-4.4%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
TOTAL
CONSUMER
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
1,231
|
|
1,294
|
-4.9%
|
-4.9%
|
-
|
|
|
5,222
|
|
5,096
|
2.5%
|
2.5%
|
-
|
|
Intl
|
|
2,089
|
|
2,312
|
-9.6%
|
5.5%
|
-15.1%
|
|
|
8,285
|
|
9,400
|
-11.9%
|
2.7%
|
-14.6%
|
|
WW
|
|
$ 3,320
|
|
3,606
|
-7.9%
|
1.8%
|
-9.7%
|
|
|
$ 13,507
|
|
14,496
|
-6.8%
|
2.7%
|
-9.5%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
REPORTED SALES vs.
PRIOR PERIOD ($MM)
|
|
|
FOURTH
QUARTER
|
|
TWELVE
MONTHS
|
|
|
|
|
|
|
%
Change
|
|
|
|
|
|
%
Change
|
|
|
|
2015
|
|
2014
|
Reported
|
Operational
(1)
|
Currency
|
|
|
2015
|
|
2014
|
Reported
|
Operational
(1)
|
Currency
|
|
PHARMACEUTICAL
SEGMENT (2) (3)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
IMMUNOLOGY
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
$ 2,101
|
|
1,816
|
15.7%
|
15.7%
|
-
|
|
|
$ 7,642
|
|
7,111
|
7.5%
|
7.5%
|
-
|
|
Intl
|
|
670
|
|
762
|
-12.1%
|
2.0%
|
-14.1%
|
|
|
2,760
|
|
3,082
|
-10.4%
|
5.5%
|
-15.9%
|
|
WW
|
|
2,771
|
|
2,578
|
7.5%
|
11.7%
|
-4.2%
|
|
|
10,402
|
|
10,193
|
2.1%
|
6.9%
|
-4.8%
|
|
REMICADE
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
1,193
|
|
1,052
|
13.4%
|
13.4%
|
-
|
|
|
4,453
|
|
4,155
|
7.2%
|
7.2%
|
-
|
|
US
Exports (4)
|
|
180
|
|
244
|
-26.2%
|
-26.2%
|
-
|
|
|
782
|
|
1,078
|
-27.5%
|
-27.5%
|
-
|
|
Intl
|
|
307
|
|
376
|
-18.4%
|
-3.9%
|
-14.5%
|
|
|
1,326
|
|
1,635
|
-18.9%
|
-4.7%
|
-14.2%
|
|
WW
|
|
1,680
|
|
1,672
|
0.5%
|
3.8%
|
-3.3%
|
|
|
6,561
|
|
6,868
|
-4.5%
|
-1.1%
|
-3.4%
|
|
SIMPONI
/ SIMPONI ARIA
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
204
|
|
164
|
24.4%
|
24.4%
|
-
|
|
|
730
|
|
544
|
34.2%
|
34.2%
|
-
|
|
Intl
|
|
136
|
|
182
|
-25.3%
|
-14.8%
|
-10.5%
|
|
|
598
|
|
643
|
-7.0%
|
10.2%
|
-17.2%
|
|
WW
|
|
340
|
|
346
|
-1.7%
|
3.8%
|
-5.5%
|
|
|
1,328
|
|
1,187
|
11.9%
|
21.2%
|
-9.3%
|
|
STELARA
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
524
|
|
356
|
47.2%
|
47.2%
|
-
|
|
|
1,677
|
|
1,334
|
25.7%
|
25.7%
|
-
|
|
Intl
|
|
218
|
|
189
|
15.3%
|
32.4%
|
-17.1%
|
|
|
797
|
|
738
|
8.0%
|
27.0%
|
-19.0%
|
|
WW
|
|
742
|
|
545
|
36.1%
|
42.0%
|
-5.9%
|
|
|
2,474
|
|
2,072
|
19.4%
|
26.2%
|
-6.8%
|
|
OTHER
IMMUNOLOGY
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
-
|
|
-
|
-
|
-
|
-
|
|
|
-
|
|
-
|
-
|
-
|
-
|
|
Intl
|
|
9
|
|
15
|
-40.0%
|
-27.7%
|
-12.3%
|
|
|
39
|
|
66
|
-40.9%
|
-30.6%
|
-10.3%
|
|
WW
|
|
9
|
|
15
|
-40.0%
|
-27.7%
|
-12.3%
|
|
|
39
|
|
66
|
-40.9%
|
-30.6%
|
-10.3%
|
|
INFECTIOUS
DISEASES
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
363
|
|
564
|
-35.6%
|
-35.6%
|
-
|
|
|
1,535
|
|
3,112
|
-50.7%
|
-50.7%
|
-
|
|
Intl
|
|
438
|
|
512
|
-14.5%
|
-3.6%
|
-10.9%
|
|
|
2,121
|
|
2,487
|
-14.7%
|
1.2%
|
-15.9%
|
|
WW
|
|
801
|
|
1,076
|
-25.6%
|
-20.4%
|
-5.2%
|
|
|
3,656
|
|
5,599
|
-34.7%
|
-27.6%
|
-7.1%
|
|
EDURANT
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
12
|
|
6
|
100.0%
|
100.0%
|
-
|
|
|
41
|
|
24
|
70.8%
|
70.8%
|
-
|
|
Intl
|
|
95
|
|
84
|
13.1%
|
29.3%
|
-16.2%
|
|
|
369
|
|
341
|
8.2%
|
29.2%
|
-21.0%
|
|
WW
|
|
107
|
|
90
|
18.9%
|
34.0%
|
-15.1%
|
|
|
410
|
|
365
|
12.3%
|
31.9%
|
-19.6%
|
|
OLYSIO /
SOVRIAD
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
(1)
|
|
256
|
**
|
**
|
-
|
|
|
173
|
|
1,943
|
-91.1%
|
-91.1%
|
-
|
|
Intl
|
|
45
|
|
65
|
-30.8%
|
-27.0%
|
-3.8%
|
|
|
448
|
|
359
|
24.8%
|
49.1%
|
-24.3%
|
|
WW
|
|
44
|
|
321
|
-86.3%
|
-85.5%
|
-0.8%
|
|
|
621
|
|
2,302
|
-73.0%
|
-69.2%
|
-3.8%
|
|
PREZISTA
/ PREZCOBIX / REZOLSTA
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
287
|
|
243
|
18.1%
|
18.1%
|
-
|
|
|
1,064
|
|
930
|
14.4%
|
14.4%
|
-
|
|
Intl
|
|
180
|
|
205
|
-12.2%
|
-0.2%
|
-12.0%
|
|
|
746
|
|
901
|
-17.2%
|
-1.6%
|
-15.6%
|
|
WW
|
|
467
|
|
448
|
4.2%
|
9.7%
|
-5.5%
|
|
|
1,810
|
|
1,831
|
-1.1%
|
6.6%
|
-7.7%
|
|
OTHER
INFECTIOUS DISEASES
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
65
|
|
59
|
10.2%
|
10.2%
|
-
|
|
|
257
|
|
215
|
19.5%
|
19.5%
|
-
|
|
Intl
|
|
118
|
|
158
|
-25.3%
|
-15.6%
|
-9.7%
|
|
|
558
|
|
886
|
-37.0%
|
-26.2%
|
-10.8%
|
|
WW
|
|
183
|
|
217
|
-15.7%
|
-8.7%
|
-7.0%
|
|
|
815
|
|
1,101
|
-26.0%
|
-17.3%
|
-8.7%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
See footnotes at end
of schedule
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
REPORTED SALES vs.
PRIOR PERIOD ($MM)
|
|
|
FOURTH
QUARTER
|
|
TWELVE
MONTHS
|
|
|
|
|
|
|
%
Change
|
|
|
|
|
|
%
Change
|
|
|
|
2015
|
|
2014
|
Reported
|
Operational
(1)
|
Currency
|
|
|
2015
|
|
2014
|
Reported
|
Operational
(1)
|
Currency
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
NEUROSCIENCE
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
752
|
|
645
|
16.6%
|
16.6%
|
-
|
|
|
2,850
|
|
2,452
|
16.2%
|
16.2%
|
-
|
|
Intl
|
|
849
|
|
1,006
|
-15.6%
|
-4.2%
|
-11.4%
|
|
|
3,409
|
|
4,035
|
-15.5%
|
-1.8%
|
-13.7%
|
|
WW
|
|
1,601
|
|
1,651
|
-3.0%
|
3.9%
|
-6.9%
|
|
|
6,259
|
|
6,487
|
-3.5%
|
5.0%
|
-8.5%
|
|
CONCERTA
/ METHYLPHENIDATE
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
117
|
|
55
|
*
|
*
|
-
|
|
|
434
|
|
152
|
*
|
*
|
-
|
|
Intl
|
|
96
|
|
114
|
-15.8%
|
-4.0%
|
-11.8%
|
|
|
387
|
|
447
|
-13.4%
|
-0.3%
|
-13.1%
|
|
WW
|
|
213
|
|
169
|
26.0%
|
33.9%
|
-7.9%
|
|
|
821
|
|
599
|
37.1%
|
46.9%
|
-9.8%
|
|
INVEGA /
PALIPERIDONE
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
58
|
|
96
|
-39.6%
|
-39.6%
|
-
|
|
|
339
|
|
360
|
-5.8%
|
-5.8%
|
-
|
|
Intl
|
|
55
|
|
65
|
-15.4%
|
-5.6%
|
-9.8%
|
|
|
234
|
|
280
|
-16.4%
|
-2.9%
|
-13.5%
|
|
WW
|
|
113
|
|
161
|
-29.8%
|
-25.9%
|
-3.9%
|
|
|
573
|
|
640
|
-10.5%
|
-4.6%
|
-5.9%
|
|
INVEGA
SUSTENNA / XEPLION / INVEGA
TRINZA
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
327
|
|
226
|
44.7%
|
44.7%
|
-
|
|
|
1,085
|
|
825
|
31.5%
|
31.5%
|
-
|
|
Intl
|
|
197
|
|
192
|
2.6%
|
17.7%
|
-15.1%
|
|
|
745
|
|
763
|
-2.4%
|
14.9%
|
-17.3%
|
|
WW
|
|
524
|
|
418
|
25.4%
|
32.4%
|
-7.0%
|
|
|
1,830
|
|
1,588
|
15.2%
|
23.5%
|
-8.3%
|
|
RISPERDAL CONSTA
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
103
|
|
104
|
-1.0%
|
-1.0%
|
-
|
|
|
409
|
|
427
|
-4.2%
|
-4.2%
|
-
|
|
Intl
|
|
131
|
|
190
|
-31.1%
|
-21.2%
|
-9.9%
|
|
|
561
|
|
763
|
-26.5%
|
-12.9%
|
-13.6%
|
|
WW
|
|
234
|
|
294
|
-20.4%
|
-14.0%
|
-6.4%
|
|
|
970
|
|
1,190
|
-18.5%
|
-9.8%
|
-8.7%
|
|
OTHER
NEUROSCIENCE
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
147
|
|
164
|
-10.4%
|
-10.4%
|
-
|
|
|
583
|
|
688
|
-15.3%
|
-15.3%
|
-
|
|
Intl
|
|
370
|
|
445
|
-16.9%
|
-6.3%
|
-10.6%
|
|
|
1,482
|
|
1,782
|
-16.8%
|
-4.5%
|
-12.3%
|
|
WW
|
|
517
|
|
609
|
-15.1%
|
-7.4%
|
-7.7%
|
|
|
2,065
|
|
2,470
|
-16.4%
|
-7.5%
|
-8.9%
|
|
ONCOLOGY
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
457
|
|
334
|
36.8%
|
36.8%
|
-
|
|
|
1,547
|
|
1,157
|
33.7%
|
33.7%
|
-
|
|
Intl
|
|
816
|
|
878
|
-7.1%
|
6.5%
|
-13.6%
|
|
|
3,148
|
|
3,300
|
-4.6%
|
12.2%
|
-16.8%
|
|
WW
|
|
1,273
|
|
1,212
|
5.0%
|
14.8%
|
-9.8%
|
|
|
4,695
|
|
4,457
|
5.3%
|
17.7%
|
-12.4%
|
|
IMBRUVICA
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
122
|
|
64
|
90.6%
|
90.6%
|
-
|
|
|
375
|
|
145
|
*
|
*
|
-
|
|
Intl
|
|
113
|
|
28
|
*
|
*
|
**
|
|
|
314
|
|
55
|
*
|
*
|
**
|
|
WW
|
|
235
|
|
92
|
*
|
*
|
**
|
|
|
689
|
|
200
|
*
|
*
|
**
|
|
VELCADE
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
-
|
|
-
|
-
|
-
|
-
|
|
|
-
|
|
-
|
-
|
-
|
-
|
|
Intl
|
|
321
|
|
418
|
-23.2%
|
-13.5%
|
-9.7%
|
|
|
1,333
|
|
1,618
|
-17.6%
|
-4.2%
|
-13.4%
|
|
WW
|
|
321
|
|
418
|
-23.2%
|
-13.5%
|
-9.7%
|
|
|
1,333
|
|
1,618
|
-17.6%
|
-4.2%
|
-13.4%
|
|
ZYTIGA
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
286
|
|
255
|
12.2%
|
12.2%
|
-
|
|
|
1,070
|
|
971
|
10.2%
|
10.2%
|
-
|
|
Intl
|
|
295
|
|
340
|
-13.2%
|
0.2%
|
-13.4%
|
|
|
1,161
|
|
1,266
|
-8.3%
|
9.0%
|
-17.3%
|
|
WW
|
|
581
|
|
595
|
-2.4%
|
5.3%
|
-7.7%
|
|
|
2,231
|
|
2,237
|
-0.3%
|
9.5%
|
-9.8%
|
|
OTHER
ONCOLOGY
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
49
|
|
15
|
*
|
*
|
-
|
|
|
102
|
|
41
|
*
|
*
|
-
|
|
Intl
|
|
87
|
|
92
|
-5.4%
|
10.3%
|
-15.7%
|
|
|
340
|
|
361
|
-5.8%
|
11.2%
|
-17.0%
|
|
WW
|
|
136
|
|
107
|
27.1%
|
40.5%
|
-13.4%
|
|
|
442
|
|
402
|
10.0%
|
25.2%
|
-15.2%
|
|
CARDIOVASCULAR /
METABOLISM /
OTHER (5)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
1,237
|
|
997
|
24.1%
|
24.1%
|
-
|
|
|
4,759
|
|
3,600
|
32.2%
|
32.2%
|
-
|
|
Intl
|
|
381
|
|
485
|
-21.4%
|
-9.8%
|
-11.6%
|
|
|
1,659
|
|
1,977
|
-16.1%
|
-3.9%
|
-12.2%
|
|
WW
|
|
1,618
|
|
1,482
|
9.2%
|
13.0%
|
-3.8%
|
|
|
6,418
|
|
5,577
|
15.1%
|
19.4%
|
-4.3%
|
|
XARELTO
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
494
|
|
428
|
15.4%
|
15.4%
|
-
|
|
|
1,868
|
|
1,522
|
22.7%
|
22.7%
|
-
|
|
Intl
|
|
-
|
|
-
|
-
|
-
|
-
|
|
|
-
|
|
-
|
-
|
-
|
-
|
|
WW
|
|
494
|
|
428
|
15.4%
|
15.4%
|
-
|
|
|
1,868
|
|
1,522
|
22.7%
|
22.7%
|
-
|
|
INVOKANA
/ INVOKAMET
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
348
|
|
193
|
80.3%
|
80.3%
|
-
|
|
|
1,238
|
|
569
|
*
|
*
|
-
|
|
Intl
|
|
24
|
|
8
|
*
|
*
|
**
|
|
|
70
|
|
17
|
*
|
*
|
**
|
|
WW
|
|
372
|
|
201
|
85.1%
|
87.1%
|
-2.0%
|
|
|
1,308
|
|
586
|
*
|
*
|
**
|
|
PROCRIT
/ EPREX
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
173
|
|
177
|
-2.3%
|
-2.3%
|
-
|
|
|
692
|
|
715
|
-3.2%
|
-3.2%
|
-
|
|
Intl
|
|
87
|
|
125
|
-30.4%
|
-20.0%
|
-10.4%
|
|
|
376
|
|
523
|
-28.1%
|
-15.8%
|
-12.3%
|
|
WW
|
|
260
|
|
302
|
-13.9%
|
-9.6%
|
-4.3%
|
|
|
1,068
|
|
1,238
|
-13.7%
|
-8.5%
|
-5.2%
|
|
OTHER
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
222
|
|
199
|
11.6%
|
11.6%
|
-
|
|
|
961
|
|
794
|
21.0%
|
21.0%
|
-
|
|
Intl
|
|
270
|
|
352
|
-23.3%
|
-12.1%
|
-11.2%
|
|
|
1,213
|
|
1,437
|
-15.6%
|
-4.1%
|
-11.5%
|
|
WW
|
|
492
|
|
551
|
-10.7%
|
-3.5%
|
-7.2%
|
|
|
2,174
|
|
2,231
|
-2.6%
|
4.8%
|
-7.4%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
TOTAL
PHARMACEUTICAL
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
4,910
|
|
4,356
|
12.7%
|
12.7%
|
-
|
|
|
18,333
|
|
17,432
|
5.2%
|
5.2%
|
-
|
|
Intl
|
|
3,154
|
|
3,643
|
-13.4%
|
-0.9%
|
-12.5%
|
|
|
13,097
|
|
14,881
|
-12.0%
|
3.0%
|
-15.0%
|
|
WW
|
|
$ 8,064
|
|
7,999
|
0.8%
|
6.5%
|
-5.7%
|
|
|
$ 31,430
|
|
32,313
|
-2.7%
|
4.2%
|
-6.9%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
See footnotes at end
of schedule
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
REPORTED SALES vs.
PRIOR PERIOD ($MM)
|
|
|
FOURTH
QUARTER
|
|
TWELVE
MONTHS
|
|
|
|
|
|
|
%
Change
|
|
|
|
|
|
%
Change
|
|
|
|
2015
|
|
2014
|
Reported
|
Operational
(1)
|
Currency
|
|
|
2015
|
|
2014
|
Reported
|
Operational
(1)
|
Currency
|
|
MEDICAL DEVICES
(2) (3)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
CARDIOVASCULAR
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
$ 229
|
|
222
|
3.2%
|
3.2%
|
-
|
|
|
$ 931
|
|
862
|
8.0%
|
8.0%
|
-
|
|
Intl
|
|
210
|
|
336
|
-37.5%
|
-29.4%
|
-8.1%
|
|
|
1,105
|
|
1,346
|
-17.9%
|
-5.3%
|
-12.6%
|
|
WW
|
|
439
|
|
558
|
-21.3%
|
-16.4%
|
-4.9%
|
|
|
2,036
|
|
2,208
|
-7.8%
|
-0.1%
|
-7.7%
|
|
DIABETES
CARE
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
202
|
|
206
|
-1.9%
|
-1.9%
|
-
|
|
|
833
|
|
864
|
-3.6%
|
-3.6%
|
-
|
|
Intl
|
|
278
|
|
308
|
-9.7%
|
5.0%
|
-14.7%
|
|
|
1,095
|
|
1,278
|
-14.3%
|
1.3%
|
-15.6%
|
|
WW
|
|
480
|
|
514
|
-6.6%
|
2.2%
|
-8.8%
|
|
|
1,928
|
|
2,142
|
-10.0%
|
-0.7%
|
-9.3%
|
|
DIAGNOSTICS
(6)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
-
|
|
-
|
-
|
-
|
-
|
|
|
-
|
|
456
|
**
|
**
|
-
|
|
Intl
|
|
24
|
|
14
|
71.4%
|
**
|
**
|
|
|
86
|
|
506
|
-83.0%
|
**
|
**
|
|
WW
|
|
24
|
|
14
|
71.4%
|
**
|
**
|
|
|
86
|
|
962
|
-91.1%
|
**
|
**
|
|
ORTHOPAEDICS
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
1,438
|
|
1,339
|
7.4%
|
7.4%
|
-
|
|
|
5,380
|
|
5,197
|
3.5%
|
3.5%
|
-
|
|
Intl
|
|
985
|
|
1,102
|
-10.6%
|
1.0%
|
-11.6%
|
|
|
3,882
|
|
4,478
|
-13.3%
|
-0.3%
|
-13.0%
|
|
WW
|
|
2,423
|
|
2,441
|
-0.7%
|
4.5%
|
-5.2%
|
|
|
9,262
|
|
9,675
|
-4.3%
|
1.7%
|
-6.0%
|
|
HIPS
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
213
|
|
194
|
9.8%
|
9.8%
|
-
|
|
|
781
|
|
745
|
4.8%
|
4.8%
|
-
|
|
Intl
|
|
141
|
|
156
|
-9.6%
|
2.3%
|
-11.9%
|
|
|
551
|
|
623
|
-11.6%
|
1.1%
|
-12.7%
|
|
WW
|
|
354
|
|
350
|
1.1%
|
6.4%
|
-5.3%
|
|
|
1,332
|
|
1,368
|
-2.6%
|
3.2%
|
-5.8%
|
|
KNEES
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
254
|
|
236
|
7.6%
|
7.6%
|
-
|
|
|
916
|
|
878
|
4.3%
|
4.3%
|
-
|
|
Intl
|
|
151
|
|
165
|
-8.5%
|
2.4%
|
-10.9%
|
|
|
580
|
|
655
|
-11.5%
|
0.7%
|
-12.2%
|
|
WW
|
|
405
|
|
401
|
1.0%
|
5.5%
|
-4.5%
|
|
|
1,496
|
|
1,533
|
-2.4%
|
2.8%
|
-5.2%
|
|
TRAUMA
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
379
|
|
352
|
7.7%
|
7.7%
|
-
|
|
|
1,462
|
|
1,418
|
3.1%
|
3.1%
|
-
|
|
Intl
|
|
265
|
|
287
|
-7.7%
|
4.6%
|
-12.3%
|
|
|
1,066
|
|
1,222
|
-12.8%
|
0.6%
|
-13.4%
|
|
WW
|
|
644
|
|
639
|
0.8%
|
6.3%
|
-5.5%
|
|
|
2,528
|
|
2,640
|
-4.2%
|
2.0%
|
-6.2%
|
|
SPINE
& OTHER
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
592
|
|
557
|
6.3%
|
6.3%
|
-
|
|
|
2,221
|
|
2,156
|
3.0%
|
3.0%
|
-
|
|
Intl
|
|
428
|
|
494
|
-13.4%
|
-2.1%
|
-11.3%
|
|
|
1,685
|
|
1,978
|
-14.8%
|
-1.8%
|
-13.0%
|
|
WW
|
|
1,020
|
|
1,051
|
-2.9%
|
2.4%
|
-5.3%
|
|
|
3,906
|
|
4,134
|
-5.5%
|
0.7%
|
-6.2%
|
|
SURGERY
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
1,044
|
|
992
|
5.2%
|
5.2%
|
-
|
|
|
3,991
|
|
3,900
|
2.3%
|
2.3%
|
-
|
|
Intl
|
|
1,369
|
|
1,484
|
-7.7%
|
4.4%
|
-12.1%
|
|
|
5,226
|
|
5,817
|
-10.2%
|
2.9%
|
-13.1%
|
|
WW
|
|
2,413
|
|
2,476
|
-2.5%
|
4.7%
|
-7.2%
|
|
|
9,217
|
|
9,717
|
-5.1%
|
2.7%
|
-7.8%
|
|
ADVANCED
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
384
|
|
352
|
9.1%
|
9.1%
|
-
|
|
|
1,430
|
|
1,342
|
6.6%
|
6.6%
|
-
|
|
Intl
|
|
486
|
|
497
|
-2.2%
|
10.1%
|
-12.3%
|
|
|
1,845
|
|
1,895
|
-2.6%
|
10.8%
|
-13.4%
|
|
WW
|
|
870
|
|
849
|
2.5%
|
9.7%
|
-7.2%
|
|
|
3,275
|
|
3,237
|
1.2%
|
9.1%
|
-7.9%
|
|
GENERAL
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
430
|
|
432
|
-0.5%
|
-0.5%
|
-
|
|
|
1,702
|
|
1,717
|
-0.9%
|
-0.9%
|
-
|
|
Intl
|
|
717
|
|
821
|
-12.7%
|
-1.3%
|
-11.4%
|
|
|
2,780
|
|
3,253
|
-14.5%
|
-1.9%
|
-12.6%
|
|
WW
|
|
1,147
|
|
1,253
|
-8.5%
|
-1.0%
|
-7.5%
|
|
|
4,482
|
|
4,970
|
-9.8%
|
-1.5%
|
-8.3%
|
|
SPECIALTY
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
230
|
|
208
|
10.6%
|
10.6%
|
-
|
|
|
859
|
|
841
|
2.1%
|
2.1%
|
-
|
|
Intl
|
|
166
|
|
166
|
0.0%
|
14.6%
|
-14.6%
|
|
|
601
|
|
669
|
-10.2%
|
4.3%
|
-14.5%
|
|
WW
|
|
396
|
|
374
|
5.9%
|
12.4%
|
-6.5%
|
|
|
1,460
|
|
1,510
|
-3.3%
|
3.1%
|
-6.4%
|
|
VISION
CARE
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
239
|
|
195
|
22.6%
|
22.6%
|
-
|
|
|
997
|
|
975
|
2.3%
|
2.3%
|
-
|
|
Intl
|
|
409
|
|
451
|
-9.3%
|
2.3%
|
-11.6%
|
|
|
1,611
|
|
1,843
|
-12.6%
|
1.5%
|
-14.1%
|
|
WW
|
|
648
|
|
646
|
0.3%
|
8.4%
|
-8.1%
|
|
|
2,608
|
|
2,818
|
-7.5%
|
1.7%
|
-9.2%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
TOTAL MEDICAL
DEVICES
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
3,152
|
|
2,954
|
6.7%
|
6.7%
|
-
|
|
|
12,132
|
|
12,254
|
-1.0%
|
-1.0%
|
-
|
|
Intl
|
|
3,275
|
|
3,695
|
-11.4%
|
0.6%
|
-12.0%
|
|
|
13,005
|
|
15,268
|
-14.8%
|
-1.7%
|
-13.1%
|
|
WW
|
|
$ 6,427
|
|
6,649
|
-3.3%
|
3.4%
|
-6.7%
|
|
|
$ 25,137
|
|
27,522
|
-8.7%
|
-1.4%
|
-7.3%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
* Percentage greater
than 100%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
** Not
meaningful
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) Operational
growth excludes the effect of translational currency
|
|
|
|
|
|
|
|
|
|
|
|
|
(2)
Unaudited
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(3) Prior year
amounts have been reclassified to conform to current year product
disclosure
|
|
|
|
|
|
|
|
|
|
|
(4) Reported as U.S.
sales
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(5) Previously
referred to as Other
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(6) Reflects
Diagnostics divestiture June 30, 2014
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/johnson--johnson-reports-2015-fourth-quarter-results-300209690.html
SOURCE Johnson & Johnson